Liposomal doxorubicin

Journal of Drug Targeting

Volumn 4, Issue 3, 1996, Pages 129-140

  Tardi, Paul G ^a   Boman, Nancy L ^a   Cullis, Pieter R ^a  

^a Inex Pharmaceuticals Corporation   (Canada)

Author keywords

Anticancer agents; Doxorubicin; Efficacy; Liposomes; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; LIPOSOME;

DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RETENTION; ENCAPSULATION; LIPID COMPOSITION; PH; PRIORITY JOURNAL; REVIEW;

EID: 0029838250     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611869609015970     Document Type: Review

References (58)

1. Abra, R.M., and Hunt, C.A. (1981) Liposome disposition in vivo: III Dose and vesicle size effects. Biochim. Biophys. Acta 666:493-503.
2. Allen, T.M., and Chonn, A. (1987) Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223:42-46.
3. Arancia, G., Molinari, A., Crateri, P., Calcabrini, A., Silvestri, L., and Isacchi, G. (1988) Adriamycin-plasma membrane interaction in human erythrocytes. Eur. J. Cell Biol. 47:379-387.
4. Balazsovits, J.A., Mayer, L.D., Bally, M.B., Cullis, P.R., McDonell, M., Ginsberg, R.S., and Falk, R.E. (1989) Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother. Pharmacol. 23:81-6.
5. Bally, M.B., Nayar, R., Masin, D., Hope, M.J., Cullis, P.R., and Mayer, L.D. (1990a) Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim. Biophys. Acta 1023:133-139.
6. Bally, M.B., Nayar, R., Masin, D., Cullis, P.R., and Mayer, L.D. (1990b) Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother. Pharmacol. 27:13-19.
7. Batist, G., Ahlgren, L., Panasci, J., Skelton, P., Gruner, D., Major, B., Leyland-Jones, B., Saletan, S., Pilkiewicz, F., and Haccoun, L. (1992) Phase II study of liposomal doxorubicin (TLC D-99) in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 11:82.
8. Beaumier, P.L., and Hwang, K.J. (1983) Effects of liposome size on the degradation of bovine brain sphingomyelin/cholesterol liposomes in mouse liver. Biochim. Biophys. Acta 731:23-30.
9. Beaumier, P., Hwang, K., and Slattery, J. (1983) Effect of liposome dose on elimination of small unilamellar sphingomyelin/cholesterol vesicles from the circulation. Res. Commun. Chem. Pathol. Pharmacol. 39:277-289.
10. Blume, G. and Cevc, C. (1990) Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta 1029:91-97.
11. Conley, B.A., Egorin, M.J., Whitacre, M.Y., Carter, D.C., Zuhowski, E.G., and Van Echo, D.A. (1993) Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother. Pharmacol. 33:107-112.
12. Cowens, J.W., Creaven, P.J., Greco, W.R., Brenner, D.E., Tung, Y., Ostro, M., Pilkiewicz, F., Ginsberg, R., and Petrelli, N. (1993) Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. 53:2796-2802.
13. Cullis, P.R., Bally, M.B., Madden, T.D., Mayer, L.D., and Hope, M.J. (1991) pH gradients and membrane transport in liposomal systems. Trends Biotechnol. 9:268-272.
14. D'Arpa, P., and Liu, L.F. (1989) Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta 989:163-177.
15. Embree, L., Gelmon, K.A., Lohr, A., Mayer, L.D., Coldman, A.J., Cullis, P.R., Palaitis, W., Pilkiewicz, F., Hudon, N.J., Heggie, J.R., and Goldie, J.H. (1993) Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small cell lung cancer patients. J. Pharm. Sci. 82:627-634.
16. Fonseca, G., Valero, V., Walters, R., Buzdar, A., Willey, J., Theriault, R., Fraschini, G., Ewer, M., Tanzola, C., Gordon, D., and Hortobagyi, G. (1994) Phase II study of TLC D-99 (liposomal) doxorubicin (LPD) in patients (PTS) with metastatic breast carcinoma (MBC). Proc. Am. Soc. Clin. Oncol. 13:66.
17. Forssen, E.A., and Tokes, Z.A. (1979) In vitro and in vivo studies with adriamycin liposomes. Biochem. Biophys. Res. Commun. 91:1295-1301.
18. Frederick, C.A., Williams, L.D., Ughetto, G., van der Marel, G.A., van Boom, J.H., Rich, A., and Wang, A.H.J. (1990) Structural comparison of anticancer drug-DNA complexes: Adriamycin and Daunomycin. Biochemistry 29:2538-2549.
19. Gabizon, A., Dagan, A., Goren, D., Barenholz, Y., and Fuks, Z. (1982) Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 42:4734-4739.
20. Gabizon, A., Goren, D., Fuks, Z., Meshoren, A., and Barenholz, Y. (1985) Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br. J. Cancer 51:681-689.
21. Gabizon, A., Peretz, T., and Ben-Yosef, R. (1986) Phase I study with liposome-associated adriamycin: Preliminary report. Proc. Am. Soc. Clin. Oncol. 5:169.
22. Gabizon, A., and Papahadjopoulous, D. (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 85:6949-6953.
23. Harashima, H., Ohshima, S., Midori, Y., Yachi, K., Kikuchi, H., and Kiwada, H. (1992) Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats: I. Biopharm. Drug Disposit. 13:155-170.
24. Harrigan, P.R., Hope, M.J., Redelmeier, T.E., and Cullis, P.R. (1992) Determination of transmembrane pH gradients and membrane potentials in liposomes. Biophys. J. 63: 1336-45.
25. Harrigan, P.R., Wong, K.F., Redelmeier, T.E., Wheeler, J.J., and Cullis, P.R. (1993) Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim. Biophys. Acta 1149:329-338.
26. Hope, M.J., Bally, M.B., Mayer, L.D., Janoff, A.S., and Cullis, P.R. (1986) Generation of multilamellar and unilamellar phospholipid vesicles. Chem. Phys. Lipids 40:89-107.
27. Horowitz, A.T., Barenholz, Y., and Gabizon, A.A. (1992) In vitro cytotoxicity of liposome-encapsulated doxorubicin: Dependence on liposome composition and drug release. Biochim. Biophys. Acta 1109:203-209.
28. Huang, S.K., Mayhew, E., Gilani, S., Lasic, D.D., Martin, FJ., and Papahadjopoulos, D. (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C26 colon carcinoma. Cancer Res. 52:6774-6781.
29. Hwang, K.J. (1987) Liposome pharmacokinetics. In Liposomes: From Biophysics to Therapeutics. Ostro, M.J. (ed.), New York, Marcel Dekker, pp. 109-156.
30. Kirby, C., Clark, J., and Gregoriadis, G. (1980) Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins. FEBS Lett. 111:324-328.
31. Klibanov, A.L., Maruyama, K., Torchilin, V.P., and Huang, L. (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:235-237.
32. Lohri, A., Gelmon, K.A., Embree, L., Mayer, L., Cullis, P., Saletan, S., and Goldie, J. (1991) Phase I/II study of liposome encapsulated doxorubicin (TLC D-99) in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 10:106.
33. Madden, T.D., Harrigan, P.R., Tai, L.C.L., Bally, M.B., Mayer, L.D., Redelmeier, T.E., Loughrey, H.C., Tilcock, C.P.S., Reinish, L.W., and Cullis, P.R. (1990) The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem. Phys. Lipids 53:37-46.
34. Martin, F., and Gabizon, A. (1992) Human pharmacokinetics of stealth liposomes containing doxorubicin. J. Cell. Biochem. 98(Suppl 16E).
35. Mayer, L.D., Hope, M.J., Cullis, P.R., and Janoff, A.S. (1985) Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim. Biophys. Acta 817:193-196.
36. Mayer, L.D., Bally, M.B., and Cullis, P.R. (1986) Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta 857:123-126.
37. Mayer, L.D., Tai, L.C.L., Ko, D.S.C., Masin, D., Ginsberg, R.S., Cullis, P.R., and Bally, M.B. (1989) Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 49, 5922-5930.
38. Mayer, L.D., Tai, L.C.L., Bally, M.B., Mitilenes, G.N., Ginsberg, R.S., and Cullis, P.R. (1990a) Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim. Biophys. Acta 1025:143-151.
39. Mayer, L.D., Bally, M.B., Cullis, P.R., Wilson, S.L., and Emerman, J.T. (1990b) Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett. 53:183-190.
40. Mayer, L.D., Bally, M.B., and Cullis, P.R. (1990c) Strategies for optimizing liposomal doxorubicin. J. Liposome Res. 1:463-480.
41. Mazanet, R., Seidenberg, S., Bartel, S., Elias, A., and Saletan, S. (1993) A phase I study of liposome encapsulated doxorubicin (TLC D-99) with G-CSF. Proc. Am. Soc. Clin. Oncol. 12:154.
42. ™ (liposomal doxorubicin) in AIDS patients with Kaposi's sarcoma (AIDS-KS). Proc. Am. Soc. Clin. Oncol. 12:51.
43. ® liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposi's sarcoma (AIDS-KS) lesions than to normal skin. Proc. Am. Soc. Clin. Oncol. 13:51.
44. O'Day, S.J., Mazanet, R., Skarin, A.T., Salgia, R., Gordon, D., and Elias, A.D. (1994) Dose escalation of liposome-encapsulated doxorubicin (D-99) with granulocyte colony stimulating factors (G-CSF) support in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 13:153.
45. Olson, F., Mayhew, E., Maslow, D., Rustum, Y., and Szoka, F. (1982) Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur. J. Cancer Clin. Oncol. 18:167-176.
46. Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.-D., Woodle, M.C., Lasic, D.D., Redemann, C., and Martin, F.J. (1991) Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88:11460-11464.
47. Rahman, A., Kessler, A., More, N., Sikic, B., Rowden, G., Woolley, P., and Schein, P.S. (1980) Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 40:1532-1537.
48. Rahman, A., Treat, J., Roh, J.K., Potkul, L.A., Alvord, W.G., Forst, D., and Wolley, P.V. (1990) A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J. Clin. Oncol. 8:1093-1100.
49. Rottenberg, H. (1989) Proton electrochemical potential gradient in vesicles, organelles, and prokaryotic cells. Methods Enzymol. 172:63-85.
50. Scherphof, G., Roerdink, F., Waite, M., and Parks, J. (1978) Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high density lipoproteins. Biochim. Biophys. Acta 842:296-307.
51. Schroit, A.J., Madsen, J.W., and Tanka, Y. (1985) In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J. Biol. Chem. 260:5131-5138.
52. Senior, J., Crawley, J.C.W., and Gregoriadis, G. (1985) Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim. Biophys. Acta 839:1-8.
53. Storm, G., Roerdink, F.H., Steerenberg, P.A., de Jong, W.H., and Crommelin, D.J.A. (1987) Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res. 47:3366-3372.
54. ® liposomal doxorubicin (D-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (AIDS-KS). Proc. Am. Soc. Clin. Oncol. 13:55.
55. Treat, J., Forst, D., Wolley, P.V., and Rahman, A. (1988) Liposome encapsulated doxorubicin (LED): A phase II study in measurable recurrent breast cancer patients. Proc. Am. Soc. Clin. Oncol. 7:41.
56. Treat, J., Greenspan, A., Forst, D., Sanchez, J.A., Ferrans, V.J., Potkul, L.A., Wolley, P.V., and Rahman, A. (1990) Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II study. J. Natl. Cancer Inst. 82:1706-1710.
57. Vaage, J., Donovan, D., Mayhew, E., Abra, R., and Huang, A. (1993) Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 72:3671-3675.
58. Woodle, M.C., Neuman, M., Collins, L.R., Redemann, C., and Martin, F.J. (1990) Proc. 17th Int. Symp. Control Release Bioactive Matr. 17:77-78.